期刊文献+

HER2/neu诱导DBA/2小鼠特异性CTL应答及其抑瘤效应研究 被引量:2

Induction of specific CTLs and anti-tumor effect in DBA/2 mice by HER2/neu genetic immunization
下载PDF
导出
摘要 目的 探讨HER2 neu原癌基因DNA疫苗免疫诱导特异性细胞免疫应答及其在体内的抑瘤效应。方法 将重组HER2 neu原癌基因真核表达载体转染P815细胞 ,用细胞组织化学及Western blot方法鉴定质粒在细胞中的表达。在DBA 2小鼠体内构建表达HER2抗原的肿瘤动物模型 ,通过重组质粒免疫小鼠 ,诱导小鼠产生细胞免疫应答 ,观察免疫动物体内的抗瘤效应。结果 在体外获得了稳定表达HER2 neu基因的P815细胞 ;免疫小鼠脾细胞中诱导出特异性CTL ,并杀伤HER2 neu阳性的P815细胞 ;荷瘤小鼠的肿瘤生长受抑 ,存活期延长。结论 HER2 neu原癌基因DNA疫苗免疫可诱导特异性细胞免疫应答 ,并具有一定抗瘤效应。 Objective To study the cellular immune response and the anti tumor effects induced by intramuscular DNA immunization with HER2/neu gene. Methods HER2/neu oncogene vector was transfected into P815 cells, and the expression of the gene DNA was identified with immunocytochemistry and Western blotting. The cellular immune response and anti tumor effects of the transfectants were analyzed by examinating the expression of HER2 in DBA/2 mice after intramuscular DNA immunization. Results P815 cells were observed to express HER2/neu oncogene in vitro . HER2/neu specific CTLs were induced in immunized DBA/2 mice, which showed specifically killing effects on HER2/neu positive P815 cells. Tumor growth was inhibited and the survival of mice was prolonged. Conclusion Specific cellular immune response and anti tumor effect are elicited by HER2/neu gene immunization.
作者 方路 吴玉章
出处 《第三军医大学学报》 CAS CSCD 北大核心 2002年第10期1137-1139,共3页 Journal of Third Military Medical University
基金 国家重点基础研究发展规划资助项目 ("973"项目 ) ( 2 0 0 1CB510 0 0 1)
关键词 HER2/NEU基因 细胞免疫 抗瘤效应 肿瘤治疗 靶抗原 DNA疫苗 HER2/neu vaccine cellular immunity anti tumor effect
  • 相关文献

参考文献8

  • 1Waalen J.DNA vaccines:The making of a revolution[K]. Ann Intem Med,1997,126(2):136-138.
  • 2Encke J, Putlittz J Z, Wands J R. DNA vaccines[J]. Intervirology, 1999,42(2-3): 117-124.
  • 3Graus-Porta D, Beerli R R, Daly J M,et al.ErbB-2,the perferred heterodimerization partner of all ErbB receptors, is a mediatior of lateral sifnaling[J].EMBO J,1997,16(7):1 647-1 655.
  • 4Wei W Z, Shi W P, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length modified human ErbB-2 DNA[J]. Int J Cancer,1999,81(5):748-754.
  • 5Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-in-filtrating T lymphocytes associated with in vivo tumor regression[J].J Immunol, 1995, 154(8):3 961-3 968.
  • 6Wang R, Doolan D L, Charoenvit Y, et al. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four plasmodium falciparum DNA plasmids[J].Infet Immun,1998,66(6):4 193-4 202.
  • 7Hoffman S L, Doolan D L, Sendegah M, et al. Toward clinical trials of DNA vaccines against malaria [J].Immunol Cell Biol,1997,75(4):376-381.
  • 8Chu R S, Targoni O S, Krieg A M, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity[J].J Exp Med,1997,186(10):1 623-1 631.

同被引文献28

  • 1崔恒,刘蓓,冯捷,昌晓红,叶雪,李艺,曹善津,付天云,姚煜,钱和年.卵巢癌抗独特型疫苗(6B11mGM)动物体内诱导抗肿瘤免疫应答的实验研究[J].解剖学报,2000,31(z1):101-105. 被引量:2
  • 2关庆东,王立新,张进平,徐薇,储以微,王缨,熊思东.ehCGβ肿瘤基因疫苗诱生的效应脾细胞过继免疫抗肿瘤作用的研究[J].中国肿瘤生物治疗杂志,2004,11(2):79-83. 被引量:1
  • 3魏于全,邓洪新,丁振宇.物治疗研究进展[J].中国临床肿瘤学教育,2004,23:20-24.
  • 4Thomp son PL, Dessureault S. Tumor cell vaccines [ J ]. Adv Exp Med Bio1,2007,601 : 345 - 355.
  • 5Uyl- de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immuno- therapy with autologous tumor cell - BCG vaccine in patients with colon cancer. A prospective study of medical and economic benefits [ J]. Vaccine ,2005,23 ( 17 - 18 ) :2379 - 2387.
  • 6Kenter GG, Welters MJ, Valentijin AR, et al. Phase I immunother- apeutic trial with long peptides spanning the E6 and E7 sequences of high - risk human papillomavirus 16 in end - stage cervical cancer patients shows low toxicity and robust immunogenicity [J].Clin Cancer Res,2008,14 ( 1 ) : 169 - 177.
  • 7Jimbo J, Sato K, Hosoki T, et al. Induction of leukemia - specific antibodies by immunotherapy with leukemia - cell - derived heat shock protein 70[J]. Cancer Sci ,2008,99(7) :1427 - 1434.
  • 8Ebert LM, Liu YC, Clements CS, et al. A long, naturally presented immunodominant epitope from NY - ESO - 1 tumor antigen : im- plications for cancer vaccine design [ J ]. Cancer Res, 2009,69 (3) :1046 - 1054.
  • 9Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and anti- tumor effects of vaccination with peptide vaccine + / - granulocyte - monoeyte colony - stimulating factor and/or IFN - alpha2b in advanced metastatic melanoma: Eastern Cooperative OncologyGroup Phase II Trial E1696 [ J]. Clin Cancer Res,2009,15 (4) : 1443 - 1451.
  • 10Honma I, Tofigoe T, Hirohashi Y, et al. Aberrant expression and potency as a cancer immunotherapy target of alpha - methylacyl - coenzyme A racemase in prostate cancer [J].Transl Med,2009, 7:103.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部